NO20032200L - Hydrolyse av [R(R*,R*)]-2-(4-fluorfenyl)-<beta>,<delta>- dihydroksy-5-(1-metyletyl)-3-fenyl-4-[(fenylamino)karbonyl]-1H-pyrrol-1-heptansyreestere med kalsiumhydroksid - Google Patents
Hydrolyse av [R(R*,R*)]-2-(4-fluorfenyl)-<beta>,<delta>- dihydroksy-5-(1-metyletyl)-3-fenyl-4-[(fenylamino)karbonyl]-1H-pyrrol-1-heptansyreestere med kalsiumhydroksidInfo
- Publication number
- NO20032200L NO20032200L NO20032200A NO20032200A NO20032200L NO 20032200 L NO20032200 L NO 20032200L NO 20032200 A NO20032200 A NO 20032200A NO 20032200 A NO20032200 A NO 20032200A NO 20032200 L NO20032200 L NO 20032200L
- Authority
- NO
- Norway
- Prior art keywords
- calcium hydroxide
- delta
- hydrolysis
- beta
- dihydroxy
- Prior art date
Links
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 title abstract 3
- 229910001861 calcium hydroxide Inorganic materials 0.000 title abstract 3
- 239000000920 calcium hydroxide Substances 0.000 title abstract 3
- 230000007062 hydrolysis Effects 0.000 title abstract 2
- 238000006460 hydrolysis reaction Methods 0.000 title abstract 2
- FQCKMBLVYCEXJB-MNSAWQCASA-L atorvastatin calcium Chemical compound [Ca+2].C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC([O-])=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1.C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC([O-])=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 FQCKMBLVYCEXJB-MNSAWQCASA-L 0.000 abstract 2
- 238000004519 manufacturing process Methods 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- PDBMVYIMAMQDCW-UHFFFAOYSA-N 3,5-dihydroxyheptanoic acid Chemical compound CCC(O)CC(O)CC(O)=O PDBMVYIMAMQDCW-UHFFFAOYSA-N 0.000 abstract 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 abstract 1
- QWOJMRHUQHTCJG-UHFFFAOYSA-N CC([CH2-])=O Chemical compound CC([CH2-])=O QWOJMRHUQHTCJG-UHFFFAOYSA-N 0.000 abstract 1
- 238000005903 acid hydrolysis reaction Methods 0.000 abstract 1
- 229960005370 atorvastatin Drugs 0.000 abstract 1
- -1 atorvastatin ester Chemical class 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 238000005580 one pot reaction Methods 0.000 abstract 1
- 239000002243 precursor Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F1/00—Compounds containing elements of Groups 1 or 11 of the Periodic Table
- C07F1/06—Potassium compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D209/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an alkyl or cycloalkyl radical attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/55—Acids; Esters
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D215/14—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/282—Organic compounds, e.g. fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pyrrole Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24931900P | 2000-11-16 | 2000-11-16 | |
| US31214401P | 2001-08-13 | 2001-08-13 | |
| US32652901P | 2001-10-01 | 2001-10-01 | |
| PCT/US2001/050639 WO2002043667A2 (en) | 2000-11-16 | 2001-10-24 | HYDROLYSIS OF [R(R*,R*)]-2-(4-FLUOROPHENYL)-β,δ -DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1-HEPTANOIC ACID ESTERS WITH CALCIUM HYDROXIDE |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20032200D0 NO20032200D0 (no) | 2003-05-15 |
| NO20032200L true NO20032200L (no) | 2003-06-24 |
Family
ID=27400196
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20032200A NO20032200L (no) | 2000-11-16 | 2003-05-15 | Hydrolyse av [R(R*,R*)]-2-(4-fluorfenyl)-<beta>,<delta>- dihydroksy-5-(1-metyletyl)-3-fenyl-4-[(fenylamino)karbonyl]-1H-pyrrol-1-heptansyreestere med kalsiumhydroksid |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US6528661B2 (da) |
| EP (1) | EP1341785B1 (da) |
| JP (1) | JP4234429B2 (da) |
| KR (1) | KR100877165B1 (da) |
| CN (1) | CN1330644C (da) |
| AT (1) | ATE410413T1 (da) |
| AU (2) | AU3289102A (da) |
| CA (1) | CA2427255A1 (da) |
| CZ (1) | CZ20031595A3 (da) |
| DE (1) | DE60136095D1 (da) |
| DK (1) | DK1341785T3 (da) |
| ES (1) | ES2313999T3 (da) |
| HR (1) | HRP20030454A2 (da) |
| HU (1) | HUP0303555A3 (da) |
| IL (1) | IL155890A0 (da) |
| IS (1) | IS6814A (da) |
| MX (1) | MXPA03004276A (da) |
| NO (1) | NO20032200L (da) |
| NZ (1) | NZ526022A (da) |
| PL (1) | PL362981A1 (da) |
| PT (1) | PT1341785E (da) |
| SK (1) | SK7212003A3 (da) |
| WO (1) | WO2002043667A2 (da) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7411075B1 (en) | 2000-11-16 | 2008-08-12 | Teva Pharmaceutical Industries Ltd. | Polymorphic form of atorvastatin calcium |
| IL156055A0 (en) * | 2000-11-30 | 2003-12-23 | Teva Pharma | Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms |
| US7501450B2 (en) * | 2000-11-30 | 2009-03-10 | Teva Pharaceutical Industries Ltd. | Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms |
| WO2002057229A1 (en) * | 2001-01-19 | 2002-07-25 | Biocon India Limited | FORM V CRYSTALLINE [R-(R*,R*)]-2-(4-FLUOROPHENYL)-ß,$G(D)-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1- HEPTANOIC ACID HEMI CALCIUM SALT. (ATORVASTATIN) |
| PL367943A1 (en) * | 2001-06-29 | 2005-03-07 | Warner-Lambert Company Llc | Crystalline forms of 'r-(r*,r*)!-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-'phenylamino)carbonyl!-1h-pyrrole-1-heptanoic acid calcium salt (2:1) (atorvastatin) |
| CZ2004126A3 (cs) * | 2001-07-30 | 2004-12-15 | Dr. Reddy's Laboratories Limited | Krystalické formy VI. A VII. vápenaté soli atorvastatinu |
| US7074818B2 (en) * | 2001-07-30 | 2006-07-11 | Dr. Reddy's Laboratories Limited | Crystalline forms VI and VII of Atorvastatin calcium |
| US7361772B2 (en) * | 2001-08-16 | 2008-04-22 | Biocon Limited | Process for the production of atorvastatin calcium |
| NZ529913A (en) * | 2001-08-16 | 2005-03-24 | Teva Pharma | Processes for preparing calcium salt forms of statins |
| US7563911B2 (en) * | 2001-08-31 | 2009-07-21 | Morepen Laboratories Ltd. | Process for the preparation of amorphous atorvastin calcium salt (2:1) |
| US20060020137A1 (en) * | 2001-11-29 | 2006-01-26 | Limor Tessler | Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms |
| US7371865B2 (en) * | 2002-01-31 | 2008-05-13 | Novartis Pharmaceuticals Corporation | Process for the manufacture of HMG-CoA reductase inhibitors |
| US7230120B2 (en) * | 2002-03-18 | 2007-06-12 | Biocon | Amorphous HMG-CoA reductase inhibitors of desired particle size |
| US7179942B2 (en) * | 2002-07-05 | 2007-02-20 | Bicon Limited | Halo-substituted active methylene compounds |
| GB0218781D0 (en) | 2002-08-13 | 2002-09-18 | Astrazeneca Ab | Chemical process |
| DE202004021379U1 (de) | 2003-02-12 | 2008-02-21 | Ciba Specialty Chemicals Holding Inc. | Kristalline Formen von Pitivastatin Calcium |
| WO2004094343A1 (en) | 2003-04-22 | 2004-11-04 | Biocon Limited | NOVEL PROCESS FOR STEREOSELECTIVE REDUCTION OF ß-KETOESTERS |
| GB0312896D0 (en) | 2003-06-05 | 2003-07-09 | Astrazeneca Ab | Chemical process |
| US7790197B2 (en) | 2003-06-09 | 2010-09-07 | Warner-Lambert Company Llc | Pharmaceutical compositions of atorvastatin |
| US7655692B2 (en) | 2003-06-12 | 2010-02-02 | Pfizer Inc. | Process for forming amorphous atorvastatin |
| US20050271717A1 (en) | 2003-06-12 | 2005-12-08 | Alfred Berchielli | Pharmaceutical compositions of atorvastatin |
| UY28501A1 (es) | 2003-09-10 | 2005-04-29 | Astrazeneca Uk Ltd | Compuestos químicos |
| JP2007505885A (ja) * | 2003-09-17 | 2007-03-15 | ワーナー−ランバート カンパニー リミティド ライアビリティー カンパニー | ［Ｒ−（Ｒ＊，Ｒ＊）］−２−（４−フルオロフェニル）−β，δ−ジヒドロキシ−５−（１−メチルエチル）−３−フェニル−４−［（フェニルアミノ）カルボニル］−１Ｈ−ピロール−１−ヘプタン酸の結晶性形態 |
| US7557238B2 (en) * | 2003-09-18 | 2009-07-07 | Biocon Limited | Process for the preparation of tert-butyl 6-cyano-5-hydroxy-3-oxohexanoate |
| GB0324791D0 (en) | 2003-10-24 | 2003-11-26 | Astrazeneca Ab | Chemical process |
| EP1711489B1 (en) * | 2003-12-29 | 2012-12-26 | LEK Pharmaceuticals d.d. | Process for preparing amorphous (4r-cis)-6-[2-[3-phenyl-4-(phenylcarbamoyl)-2-(4-fluorophenyl)-5-(1-methyl)-pyrrol-1-yl]-2,2-dimethyl-[1,3]-dioxane-4-yl-acetic acid |
| SI21745A (sl) * | 2004-04-09 | 2005-10-31 | Krka, Tovarna Zdravil, D.D., Novo Mesto | Polimorfi derivata 1-pirol-1-heptanojske kisline, intermediata za pripravo atorvastatina |
| US7875731B2 (en) | 2004-05-05 | 2011-01-25 | Pfizer Inc. | Salt forms of [R-(R*,R*)]-2-(4-fluorophenyl)-β, δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)Carbonyl]-1H-pyrrole-1-heptanoic acid |
| CA2833770A1 (en) * | 2004-07-16 | 2006-01-26 | Lek Pharmaceuticals D.D | Oxidative degradation products of atorvastatin calcium |
| BRPI0513422A (pt) | 2004-07-20 | 2008-05-06 | Warner Lambert Co | formas de sais cálcio do ácido (r-(r*))-2-(4- fluorfenil)-(beta), (sigma)-diidróxi-5-(1-metiletil) -3-fenil-4-((fenilamino) carbonil)-1h-pirrol-1-heptanóico (2:1) |
| NZ554541A (en) | 2004-10-28 | 2011-01-28 | Warner Lambert Co | Process for forming amorphous atorvastatin |
| CA2499047A1 (en) * | 2005-03-01 | 2006-09-01 | Apotex Pharmachem Inc. | Process for producing atorvastatin hemicalcium |
| CA2601111A1 (en) * | 2005-03-14 | 2006-09-21 | Pfizer Science And Technology Ireland Limited | Preparation of an atorvastatin intermediate using a paal-knorr condensation |
| CA2621506A1 (en) * | 2005-09-09 | 2007-03-15 | Pfizer Science And Technology Ireland Limited | Preparation of an atorvastatin intermediate |
| US20090221852A1 (en) * | 2005-09-09 | 2009-09-03 | Pfizer Inc. | Preparation of an Atorvastatin Intermediate |
| CA2547216A1 (en) | 2005-09-21 | 2007-03-21 | Renuka D. Reddy | Process for annealing amorphous atorvastatin |
| ES2304335T3 (es) | 2005-11-21 | 2010-05-19 | Warner-Lambert Company Llc | Formas nuevas del acido (r-(r*,r*))-2-(4-fluorofenil)-b,b-dihidroxi-5-(1-metiletil)-3-fenil-4-((fenilamino)carbonil)1h-pirrol-1-heptanoico, de magnesio. |
| US8080672B2 (en) * | 2005-12-13 | 2011-12-20 | Teva Pharmaceutical Industries Ltd. | Crystal form of atorvastatin hemi-calcium and processes for preparation thereof |
| CN101395132A (zh) * | 2006-03-01 | 2009-03-25 | 特瓦制药工业有限公司 | 制备阿托伐他汀半钙的晶形的方法 |
| WO2009082362A1 (en) * | 2007-11-05 | 2009-07-02 | Ulkar Kimya San. Ve Tic. A.S. | A method for producing statins in pure form |
| KR100850850B1 (ko) * | 2008-01-25 | 2008-08-06 | 주식회사종근당 | 아토르바스타틴의 제조방법 및 이에 사용되는 중간체 |
| US11473032B2 (en) | 2010-02-02 | 2022-10-18 | Fuchs Petrolub Se | Constant velocity joint having a boot |
| US20130041162A1 (en) * | 2010-04-19 | 2013-02-14 | Dsm Sinochem Pharmaceuticals Netherlands B.V. | Production of atorvastatin low in ether impurities |
| US20130041163A1 (en) * | 2010-04-19 | 2013-02-14 | Dsm Sinochem Pharmaceuticals Netherlands B.V. | Production of atorvastatin low in lactone impurities |
| JP5843406B2 (ja) | 2014-02-19 | 2016-01-13 | 株式会社オートネットワーク技術研究所 | 金属表面コーティング用組成物およびこれを用いた端子付き被覆電線 |
| CN104447487A (zh) * | 2014-12-07 | 2015-03-25 | 河南豫辰药业股份有限公司 | 一种阿托伐他汀半钙的制备方法 |
| JP6830051B2 (ja) * | 2017-10-11 | 2021-02-17 | 東レ・ファインケミカル株式会社 | 高純度トリフルオロメチル基置換芳香族ケトンの製造方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4137322A (en) * | 1976-11-02 | 1979-01-30 | Sankyo Company Limited | ML-236B carboxylic acid derivatives and their use as antihyperlipemic agents |
| US4681893A (en) | 1986-05-30 | 1987-07-21 | Warner-Lambert Company | Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis |
| US5149837A (en) | 1988-02-22 | 1992-09-22 | Warner-Lambert Company | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
| US5245047A (en) | 1988-02-22 | 1993-09-14 | Warner-Lambert Company | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
| US5216174A (en) | 1988-02-22 | 1993-06-01 | Warner-Lambert Co. | Process for trans-6-[12-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
| US5097045A (en) | 1989-02-01 | 1992-03-17 | Warner-Lambert Company | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
| US5003080A (en) | 1988-02-22 | 1991-03-26 | Warner-Lambert Company | Process for trans-6-(2-(substituted-pyrrol-1-yl)alkyl)pryan-2-one inhibitors of cholesterol synthesis |
| US5124482A (en) | 1988-02-22 | 1992-06-23 | Warner-Lambert Company | Process for trans-6-(2-substituted-pyrrol-1-yl)alkyl)pyran-2-one inhibitors of cholesterol synthesis |
| FI94339C (fi) * | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi |
| US5298627A (en) * | 1993-03-03 | 1994-03-29 | Warner-Lambert Company | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
| HRP960312B1 (en) | 1995-07-17 | 2001-10-31 | Warner Lambert Co | NOVEL PROCESS FOR THE PRODUCTION OF AMORPHOUS /R-(R*, R*)/-2-(4-FLUOROPHENYL)-"beta", "delta"-DIHYDROXY-5-PHENYL-4-/(PHENYLAMINO)CARBONYL/-1H-PYRROLE -1-HEPTANOIC ACID CALCIUM SALT (2 : 1) |
| IL156055A0 (en) * | 2000-11-30 | 2003-12-23 | Teva Pharma | Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms |
| NZ529913A (en) * | 2001-08-16 | 2005-03-24 | Teva Pharma | Processes for preparing calcium salt forms of statins |
-
2001
- 2001-10-24 DK DK01992422T patent/DK1341785T3/da active
- 2001-10-24 AT AT01992422T patent/ATE410413T1/de not_active IP Right Cessation
- 2001-10-24 PT PT01992422T patent/PT1341785E/pt unknown
- 2001-10-24 CA CA002427255A patent/CA2427255A1/en not_active Withdrawn
- 2001-10-24 CN CNB018219683A patent/CN1330644C/zh not_active Expired - Fee Related
- 2001-10-24 MX MXPA03004276A patent/MXPA03004276A/es active IP Right Grant
- 2001-10-24 NZ NZ526022A patent/NZ526022A/en unknown
- 2001-10-24 ES ES01992422T patent/ES2313999T3/es not_active Expired - Lifetime
- 2001-10-24 AU AU3289102A patent/AU3289102A/xx active Pending
- 2001-10-24 SK SK721-2003A patent/SK7212003A3/sk not_active Application Discontinuation
- 2001-10-24 EP EP01992422A patent/EP1341785B1/en not_active Expired - Lifetime
- 2001-10-24 US US10/037,412 patent/US6528661B2/en not_active Expired - Fee Related
- 2001-10-24 CZ CZ20031595A patent/CZ20031595A3/cs unknown
- 2001-10-24 DE DE60136095T patent/DE60136095D1/de not_active Expired - Lifetime
- 2001-10-24 JP JP2002545646A patent/JP4234429B2/ja not_active Expired - Fee Related
- 2001-10-24 HU HU0303555A patent/HUP0303555A3/hu unknown
- 2001-10-24 AU AU2002232891A patent/AU2002232891B2/en not_active Ceased
- 2001-10-24 IL IL15589001A patent/IL155890A0/xx unknown
- 2001-10-24 KR KR1020037006582A patent/KR100877165B1/ko not_active IP Right Cessation
- 2001-10-24 PL PL01362981A patent/PL362981A1/xx not_active Application Discontinuation
- 2001-10-24 WO PCT/US2001/050639 patent/WO2002043667A2/en active IP Right Grant
-
2003
- 2003-05-14 IS IS6814A patent/IS6814A/is unknown
- 2003-05-15 NO NO20032200A patent/NO20032200L/no not_active Application Discontinuation
- 2003-06-05 HR HR20030454A patent/HRP20030454A2/hr not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CN1330644C (zh) | 2007-08-08 |
| SK7212003A3 (en) | 2004-03-02 |
| US6528661B2 (en) | 2003-03-04 |
| EP1341785B1 (en) | 2008-10-08 |
| US20020099224A1 (en) | 2002-07-25 |
| MXPA03004276A (es) | 2005-04-29 |
| IS6814A (is) | 2003-05-14 |
| JP4234429B2 (ja) | 2009-03-04 |
| EP1341785A2 (en) | 2003-09-10 |
| NO20032200D0 (no) | 2003-05-15 |
| HUP0303555A3 (en) | 2005-08-29 |
| ES2313999T3 (es) | 2009-03-16 |
| CN1561341A (zh) | 2005-01-05 |
| HUP0303555A2 (hu) | 2004-03-01 |
| ATE410413T1 (de) | 2008-10-15 |
| AU2002232891B2 (en) | 2006-12-14 |
| NZ526022A (en) | 2005-04-29 |
| AU3289102A (en) | 2002-06-11 |
| PT1341785E (pt) | 2009-01-16 |
| CZ20031595A3 (cs) | 2003-11-12 |
| EP1341785A4 (en) | 2004-05-12 |
| KR100877165B1 (ko) | 2009-01-07 |
| DK1341785T3 (da) | 2009-01-26 |
| KR20030059253A (ko) | 2003-07-07 |
| HRP20030454A2 (en) | 2005-10-31 |
| PL362981A1 (en) | 2004-11-02 |
| JP2004514687A (ja) | 2004-05-20 |
| CA2427255A1 (en) | 2002-06-06 |
| WO2002043667A2 (en) | 2002-06-06 |
| WO2002043667A3 (en) | 2002-10-10 |
| DE60136095D1 (de) | 2008-11-20 |
| IL155890A0 (en) | 2003-12-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20032200L (no) | Hydrolyse av [R(R*,R*)]-2-(4-fluorfenyl)-<beta>,<delta>- dihydroksy-5-(1-metyletyl)-3-fenyl-4-[(fenylamino)karbonyl]-1H-pyrrol-1-heptansyreestere med kalsiumhydroksid | |
| BR0116785A (pt) | Processo para a sìntese da forma v de atorvastatina e fenilboronatos como compostos intermediários | |
| YU56803A (sh) | Pripremanje nekristalinskog atorvastatin-kalcijuma | |
| UY24985A1 (es) | Formas cristalinas hidratadas de atorvastatina forma i | |
| CA2392025A1 (en) | Process for the preparation of amorphous atorvastatin | |
| NO20035675D0 (no) | Krystallinske former av (R-(R*,R*))-2-(4-fluorfenyl)- <beta>,<delta>-dihydroksy-5-(1-metyletyl)-3-fenyl-4-(fenylamino)karbonyl)-1H-pyrrol-1-heptansyre-kalsiumsalt (2:1) (Atorvastatin) | |
| TW200724688A (en) | Process for producing atorvastatin, pharmaceutically acceptable salts thereof and intermediates thereof | |
| EE9800016A (et) | Vorm III kristalliline [R-(R*,R*)]-2-(4-fluorofenüül)-beeta, delta-dihüdroksü-5-(1-metüületüül)-3-fenüül-4-[(fenüülamino)karbonüül]-1H-pürrool-1-hepta anhappe hemikaltsiumsool (atorvastatiin) | |
| MX9708959A (es) | PROCESO NOVEDOSO PARA LA PRODUCCION DE SAL DE CALCIO DE ACIDO [R-(R*R*)]-2-(4-FLUOROFENIL)- beta,&-DIHIDROXI-5-(1-METILETIL)-3 -FENIL-4-[(FENILAMINO)CARBONIL)-1H-PIRROLE-1-HEPTANOICO AMORFO (2:1). | |
| WO2005014539A3 (en) | Pyrrole-based hmg-coa reductase inhibitors | |
| MXPA04000889A (es) | Formas cristalinas vi y vii de atorvastatina calcica. | |
| HUP0402590A3 (en) | Method of manufacturing an amorphous form of the hemi-calcium salt of (3r,5r)7-3-phenyl-4-phenylcarbomoyl-2-(4-fluorophenyl)-5-isopropyl-pyrrol-1-yl!-3, 5-dihydroxyheptanoic acid (atorvastatin) | |
| NZ534232A (en) | Process for the manufacture of hmg-coa reductase inhibitors | |
| EA200700331A1 (ru) | КРИСТАЛЛИЧЕСКАЯ КАЛЬЦЕВАЯ СОЛЬ [R-(R*,R*)]-2-(4-ФТОРФЕНИЛ)- β, δ-ДИГИДРОКСИ-5-(1-МЕТИЛЭТИЛ)-3-ФЕНИЛ-4-[(ФЕНИЛАМИНО)КАРБОНИЛ]-1H-ПИРРОЛ-ГЕПТАНОВОЙ КИСЛОТЫ | |
| IL173651A0 (en) | Crystalline forms of [r-(r*,r*)]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid | |
| BRPI0417138A (pt) | n-alquil-pirroles como inibidores de hmg-coa-redutase | |
| NZ512207A (en) | Process for producing quinolinecarbaldehyde | |
| EA200400391A1 (ru) | Полиморфные формы производного 1-пиррола, промежуточного соединения для получения аторвастатина | |
| WO2008053495A1 (en) | A novel crystalline form of atorvastatin sodium | |
| ZA200303974B (en) | Hydrolysis of [R(R*,R*)]-2-(4-Fluorophenyl)-b,D-Dihydroxy-5-(1-Methylethyl)-3-Phenyl-4-[(Phenylamino)Carbonyl]-1H-Pyrrole-1-Heptanoic acid esters with calcium hydroxide. | |
| HUP0600120A2 (en) | New crystalline atorvastatin hemicalcium, pharmaceutical composition containing it and process for producing it | |
| RU2004126965A (ru) | Аморфные ингибиторы гмг-коа-редуктазы и способ их получения |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |